Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of single ascending doses of APD 371 in healthy adult volunteers

Next Previous
Trial Profile

Randomised, double-blind, placebo-controlled phase I trial evaluating the safety, tolerability and pharmacokinetics of single ascending doses of APD 371 in healthy adult volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olorinab (Primary)
  • Indications Abdominal pain
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 23 Sep 2020 Results assessing safety and PK of single and multiple doses of olorinab in healthy adults from SAD and MAD studies presented at the 2020 American College of Clinical Pharmacology Annual Meeting
  • 21 Mar 2020 Results assessing single and multiple dose PK and safety of olorinab in healthy adult subjects, presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
  • 07 Feb 2019 According to an Arena Pharmaceuticals media release, data from the study will be presented at Crohn's & Colitis Congress 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top